2020
A prospective study of the association between rate of nicotine metabolism and alcohol use in tobacco users in the United States
Roberts W, Marotta PL, Verplaetse TL, Peltier MR, Burke C, Ramchandani VA, McKee SA. A prospective study of the association between rate of nicotine metabolism and alcohol use in tobacco users in the United States. Drug And Alcohol Dependence 2020, 216: 108210. PMID: 32805549, PMCID: PMC7609495, DOI: 10.1016/j.drugalcdep.2020.108210.Peer-Reviewed Original ResearchConceptsNicotine metabolite ratioRisk factorsAlcohol useTobacco usersNicotine metabolismTrans-3'-HydroxycotinineWave 1Biochemical risk factorsAlcohol consumption amountCurrent tobacco usersNicotine metabolism rateAssociated health outcomesSex differencesAlcohol use outcomesCigarette smokersNicotine exposureProspective studyOdds ratioTobacco useDrinking statusHealth StudyAlcohol consumptionNicotine useMetabolite ratiosHealth outcomesAssociations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study
Verplaetse TL, Peltier MR, Roberts W, Moore KE, Pittman BP, McKee SA. Associations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study. Nicotine & Tobacco Research 2020, 22: 1316-1321. PMID: 32152625, PMCID: PMC7364844, DOI: 10.1093/ntr/ntaa022.Peer-Reviewed Original ResearchConceptsNicotine metabolite ratioFaster nicotine metabolismHigher nicotine metabolite ratioE-cigarette useCigarette smoking statusSlower nicotine metabolismNicotine metabolismE-cigarettesSmoking statusCigarette smokingMetabolite ratiosE-cigarette use statusPopulation-based studyLongitudinal cohort studyWave 1Cigarette smoking behaviorCohort studyClinical trialsTobacco usePATH studyHealth StudySmoking behaviorEarly interventionUS populationCombustible cigarettes
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differences
2016
An overview of alcohol and tobacco/nicotine interactions in the human laboratory
Verplaetse TL, McKee SA. An overview of alcohol and tobacco/nicotine interactions in the human laboratory. The American Journal Of Drug And Alcohol Abuse 2016, 43: 186-196. PMID: 27439453, PMCID: PMC5588903, DOI: 10.1080/00952990.2016.1189927.Peer-Reviewed Original ResearchConceptsAlcohol-tobacco interactionsNicotine interactionsHuman laboratorySubjective responsesBlood alcohol curveDrinking cuesAlcohol use disorderOverview of alcoholNicotine deprivationSelf-administration behaviorDrugs of abuseAlcohol cravingReciprocal influenceAlcohol curveAlcohol influenceSubjective effectsUse disordersTobacco/nicotineNicotine administrationTobacco useInteractive effectsCravingMajor public health concernPublic health concernDrinkersTargeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings
Verplaetse TL, McKee SA. Targeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings. Current Addiction Reports 2016, 3: 314-322. PMID: 31275802, PMCID: PMC6609087, DOI: 10.1007/s40429-016-0115-x.Peer-Reviewed Original ResearchBrain stress systemsTobacco useNoradrenergic systemTreatment strategiesCorticotropin-releasing factor (CRF) systemTobacco/nicotine dependenceMajority of smokersNicotine-induced activationPotential treatment strategySmoking-related outcomesNicotine-motivated behaviorsLong-term abstinenceStress systemClinical findingsAdrenal axisTobacco dependencePreventable mortalityClinical investigationNicotine dependenceRecent FindingsOneTherapeutic benefitPharmacological agentsCRF systemDrug AdministrationSummaryThis review
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen